ES3038392T3 - Neoantigen specific cytotoxic t cells for use in treating cancer - Google Patents

Neoantigen specific cytotoxic t cells for use in treating cancer

Info

Publication number
ES3038392T3
ES3038392T3 ES19219395T ES19219395T ES3038392T3 ES 3038392 T3 ES3038392 T3 ES 3038392T3 ES 19219395 T ES19219395 T ES 19219395T ES 19219395 T ES19219395 T ES 19219395T ES 3038392 T3 ES3038392 T3 ES 3038392T3
Authority
ES
Spain
Prior art keywords
peptide
mutation
tumor
subject
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19219395T
Other languages
English (en)
Spanish (es)
Inventor
Nir Hacohen
Catherine Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Dana Farber Cancer Institute Inc
Original Assignee
General Hospital Corp
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44915022&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES3038392(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by General Hospital Corp, Dana Farber Cancer Institute Inc filed Critical General Hospital Corp
Application granted granted Critical
Publication of ES3038392T3 publication Critical patent/ES3038392T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G01N33/575—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
ES19219395T 2010-05-14 2011-05-16 Neoantigen specific cytotoxic t cells for use in treating cancer Active ES3038392T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33486610P 2010-05-14 2010-05-14

Publications (1)

Publication Number Publication Date
ES3038392T3 true ES3038392T3 (en) 2025-10-13

Family

ID=44915022

Family Applications (3)

Application Number Title Priority Date Filing Date
ES11781409.5T Active ES2564841T3 (es) 2010-05-14 2011-05-16 Composiciones y métodos para identificar neoantígenos específicos de un tumor
ES15198284T Active ES2788863T3 (es) 2010-05-14 2011-05-16 Composiciones de neoantígenos específicos de un tumor para uso en el tratamiento de tumores
ES19219395T Active ES3038392T3 (en) 2010-05-14 2011-05-16 Neoantigen specific cytotoxic t cells for use in treating cancer

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES11781409.5T Active ES2564841T3 (es) 2010-05-14 2011-05-16 Composiciones y métodos para identificar neoantígenos específicos de un tumor
ES15198284T Active ES2788863T3 (es) 2010-05-14 2011-05-16 Composiciones de neoantígenos específicos de un tumor para uso en el tratamiento de tumores

Country Status (14)

Country Link
US (8) US9115402B2 (enExample)
EP (4) EP2569633B1 (enExample)
JP (5) JP5948319B2 (enExample)
KR (4) KR102315754B1 (enExample)
CN (2) CN103180730B (enExample)
AU (1) AU2011252795B2 (enExample)
BR (2) BR122021014039B1 (enExample)
CA (2) CA3197245A1 (enExample)
DK (1) DK3023788T3 (enExample)
ES (3) ES2564841T3 (enExample)
HU (1) HUE049886T2 (enExample)
PL (1) PL3023788T3 (enExample)
PT (1) PT3023788T (enExample)
WO (1) WO2011143656A2 (enExample)

Families Citing this family (178)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
EP3101122B1 (en) 2009-08-24 2023-06-14 Baylor College of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
DK3023788T3 (da) * 2010-05-14 2020-04-27 Massachusetts Gen Hospital Sammensætninger af tumorspecifikke neoantigener til anvendelse ved behandling af tumorer
RS59369B1 (sr) * 2011-05-24 2019-11-29 Biontech Rna Pharmaceuticals Gmbh Individualizovane vakcine protiv kancera
HRP20230443T1 (hr) 2011-05-24 2023-09-15 BioNTech SE Individualizirana cjepiva protiv raka
ES2739828T3 (es) * 2011-08-02 2020-02-04 Univ Tokyo Método para la evaluación de la predisposición al síndrome mielodisplásico o al tumor mieloide, polipéptido y anticuerpo para ello, y método de cribaje de candidatos para el fármaco terapéutico o el fármaco profiláctico para ello
ES2602072T3 (es) * 2011-09-29 2017-02-17 Trovagene, Inc. Mutaciones en SF3B1 y leucemia linfocítica crónica
WO2013086464A1 (en) * 2011-12-07 2013-06-13 The Broad Institute, Inc. Markers associated with chronic lymphocytic leukemia prognosis and progression
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
PL2812431T3 (pl) 2012-02-09 2020-02-28 Baylor College Of Medicine Mieszanki peptydowe do wytwarzania wielowirusowych CTL o szerokiej swoistości
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
CA2886218A1 (en) 2012-05-25 2013-11-28 Phosimmune, Inc. Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies
AU2013289939B2 (en) * 2012-07-12 2018-08-09 Persimmune, Inc. Personalized cancer vaccines and adoptive immune cell therapies
GB201214007D0 (en) * 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
EP2897631A4 (en) * 2012-08-31 2016-10-05 Univ Virginia Patent Found TARGET PEPTIDES FOR IMMUNOTHERAPY AND DIAGNOSTICS
AU2013312529A1 (en) 2012-09-05 2015-04-16 The University Of Birmingham Target peptides for colorectal cancer therapy and diagnostics
ES2737757T3 (es) * 2012-09-28 2020-01-15 Univ Connecticut Identificación de epítopos protectores contra tumores para el tratamiento de cánceres
AU2013351542B2 (en) * 2012-11-28 2018-08-09 BioNTech SE Individualized vaccines for cancer
GB2508414A (en) * 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
EP3292873B1 (en) 2013-02-22 2019-05-01 CureVac AG Combination of vaccination and inhibition of the pd-1 pathway
AU2014220957A1 (en) 2013-02-22 2015-07-30 Curevac Ag Combination of vaccination and inhibition of the PD-1 pathway
KR102164405B1 (ko) 2013-03-14 2020-10-12 더 존스 홉킨스 유니버시티 나노스케일 인공 항원 제시 세포
KR102858313B1 (ko) * 2013-04-07 2025-09-10 더 브로드 인스티튜트, 인코퍼레이티드 개인맞춤화 신생물 백신을 위한 조성물 및 방법
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
KR102429859B1 (ko) * 2013-12-06 2022-08-04 더 브로드 인스티튜트, 인코퍼레이티드 신생물 백신을 위한 제형
KR20230076867A (ko) * 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
RU2707530C2 (ru) * 2014-01-02 2019-11-27 Мемориал Слоан Кеттеринг Кэнсер Сентер Детерминанты ответа раковой опухоли на иммунотерапию
EP3590529A1 (en) 2014-03-12 2020-01-08 CureVac AG Combination of vaccination and ox40 agonists
CA2945816A1 (en) 2014-04-15 2015-10-22 University Of Virginia Patent Foundation Isolated t cell receptors and methods of use therefor
WO2016040110A1 (en) * 2014-09-10 2016-03-17 The University Of Connecticut Identification of immunologically protective neo-epitopes for the treatment of cancers
US11338026B2 (en) 2014-09-10 2022-05-24 The University Of Connecticut Identification of immunologically protective neo-epitopes for the treatment of cancers
JP7044551B2 (ja) 2014-09-10 2022-03-30 ジェネンテック， インコーポレイテッド 免疫原性変異体ペプチドスクリーニングプラットフォーム
WO2016040900A1 (en) * 2014-09-14 2016-03-17 Washington University Personalized cancer vaccines and methods therefor
CA2961749C (en) 2014-09-17 2021-01-12 The Johns Hopkins University Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells
LT3193917T (lt) * 2014-09-17 2021-11-25 Io Biotech Aps Vakcinų kompozicijos, apimančios triptofan-2,3-dioksigenazę arba jos fragmentus
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016053339A1 (en) 2014-10-02 2016-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cells having antigenic specificity for a cancer-specific mutation
KR20170072244A (ko) * 2014-10-10 2017-06-26 이데라 파마슈티칼즈, 인코포레이티드 관문 억제제를 가지는 tlr9 효능제를 이용한 암 치료
MA40737A (fr) * 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
WO2016128060A1 (en) * 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
MX2017012131A (es) 2015-03-25 2018-06-15 Univ Michigan Regents Composiciones y métodos para la administración de agentes de biomacromoléculas.
US20190099475A1 (en) 2015-04-08 2019-04-04 Nantomics, Llc Cancer neoepitopes
BR112017022845A2 (pt) 2015-04-23 2018-07-17 Nantomics, Llc neoepítopos de câncer
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
RU2770447C2 (ru) * 2015-04-27 2022-04-18 Кэнсэр Ресерч Текнолоджи Лимитед Способ лечения рака
WO2016179006A1 (en) 2015-05-01 2016-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
SG10201912485PA (en) 2015-05-13 2020-02-27 Agenus Inc Vaccines for treatment and prevention of cancer
WO2016187508A2 (en) * 2015-05-20 2016-11-24 The Broad Institute Inc. Shared neoantigens
TW202241500A (zh) * 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
JP2018524008A (ja) 2015-07-14 2018-08-30 パーソナル ジノーム ダイアグノスティクス， インコーポレイテッド ネオアンチゲン分析
EP3328394A4 (en) 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
SG10202112047TA (en) * 2015-09-18 2021-12-30 Baylor College Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
CN108701173A (zh) * 2015-10-12 2018-10-23 南托米克斯有限责任公司 用于发现预测对检查点抑制剂敏感的msi和新表位的系统、组合物和方法
CN108604257B (zh) * 2015-10-12 2022-12-13 南托米克斯有限责任公司 产生特异性免疫治疗组合物及其相关核酸构建体的方法
US11623001B2 (en) * 2015-10-12 2023-04-11 Nantomics, Llc Compositions and methods for viral cancer neoepitopes
WO2017066339A1 (en) * 2015-10-12 2017-04-20 Nantomics, Llc Iterative discovery of neoepitopes and adaptive immunotherapy and methods therefor
CA3003090A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Cancer vaccines
CA3004504A1 (en) 2015-11-06 2017-05-11 Ventana Medical Systems, Inc. Tissue homogenisation for representative diagnostics
TWI733719B (zh) 2015-12-07 2021-07-21 美商河谷控股Ｉｐ有限責任公司 改善的組合物及用於新表位之病毒遞送的方法及其應用
TWI765875B (zh) 2015-12-16 2022-06-01 美商磨石生物公司 新抗原辨識、製造及用途
CA3048204A1 (en) * 2015-12-23 2017-06-29 Moonshot Pharma Llc Methods for inducing an immune response
CA3008437A1 (en) 2016-01-08 2017-07-13 Vaccibody As Therapeutic anticancer neoepitope vaccine
US20170224796A1 (en) 2016-02-05 2017-08-10 Xeme Biopharma Inc. Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
KR20180091119A (ko) * 2016-02-12 2018-08-14 난토믹스, 엘엘씨 암 면역요법을 위한 치료 표적으로 환자 특이적 네오에피토프의 높은 스루풋 식별 (high-throughput identification of patient-specific neoepitopes as therapeutic targets for cancer immunotherapies)
JP2019511903A (ja) 2016-02-19 2019-05-09 ナント ホールディングス アイピー エルエルシーＮａｎｔ Ｈｏｌｄｉｎｇｓ ＩＰ， ＬＬＣ 免疫原性調節の方法
CN105720176A (zh) * 2016-02-19 2016-06-29 京东方科技集团股份有限公司 一种胶囊量子点和发光二极管、制备方法及显示装置
EP3475434A4 (en) * 2016-03-24 2020-07-29 Nantcell, Inc. SEQUENCES AND SEQUENCES ARRANGEMENTS FOR PRESENTATION OF NEO-EPITOPIA
WO2017177207A1 (en) * 2016-04-07 2017-10-12 Bostongene, Llc Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines
US20190062272A1 (en) * 2016-04-13 2019-02-28 Capten Therapeutics Inc. Small molecules for immunogenic treatment of cancer
US12257352B2 (en) 2016-06-20 2025-03-25 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
US20190247435A1 (en) * 2016-06-29 2019-08-15 The Johns Hopkins University Neoantigens as targets for immunotherapy
CN109789092A (zh) 2016-07-13 2019-05-21 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
WO2018015433A2 (en) * 2016-07-20 2018-01-25 Biontech Rna Pharmaceuticals Gmbh Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy
KR20190031573A (ko) * 2016-08-02 2019-03-26 난트셀, 인크. 수지상 세포들의 형질주입 및 그 방법들(transfection of dendritic cells and methods therefor)
US20190237158A1 (en) * 2016-08-31 2019-08-01 Medgenome, Inc. Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore
US10350280B2 (en) 2016-08-31 2019-07-16 Medgenome Inc. Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore
JP7200093B2 (ja) 2016-09-15 2023-01-06 アイデラ・ファーマシューティカルズ，インコーポレーテッド がん治療用ｔｌｒ９アゴニストを用いた免疫調節
US11976299B2 (en) 2016-09-23 2024-05-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same
WO2018071796A2 (en) * 2016-10-13 2018-04-19 The Johns Hopkins University Compositions and methods for identifying functional anti-tumor t cell responses
EP4338799A3 (en) * 2016-10-18 2024-06-05 Regents of the University of Minnesota Tumor infiltrating lymphocytes and methods of therapy
US20190321481A1 (en) 2016-11-11 2019-10-24 Nantbio, Inc. Immunomodulatory compositions, processes for making the same, and methods for inhibiting cytokine storms
JP2020507557A (ja) 2016-12-01 2020-03-12 ナントミクス，エルエルシー 腫瘍抗原性の処理および提示
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
MX2019009070A (es) * 2017-02-01 2019-10-30 Modernatx Inc Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion.
EP3576751A4 (en) * 2017-02-01 2021-08-04 ModernaTX, Inc. RNA ANTI-CANCER VACCINES
BR112019019407A2 (pt) 2017-03-20 2020-05-26 Genocea Biosciences Inc. Métodos de tratamento
WO2018183544A1 (en) * 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Method for identification of retained intron tumor neoantigens from patient transcriptome
US12303561B2 (en) 2017-04-03 2025-05-20 Biontech Us Inc. Protein antigens and uses thereof
CA3057715A1 (en) 2017-04-04 2018-10-11 Avidea Technologies, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
CA3060569A1 (en) * 2017-04-19 2018-10-25 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
IL270132B2 (en) 2017-04-24 2024-12-01 Nantcell Inc Neoepitope vectors and methods for them
WO2018208856A1 (en) 2017-05-08 2018-11-15 Gritstone Oncology, Inc. Alphavirus neoantigen vectors
EP3622068B1 (en) 2017-05-10 2024-02-28 The Broad Institute, Inc. Methods for determination of mutations in single replication events
EP3622092A4 (en) 2017-05-11 2021-06-23 The Broad Institute, Inc. METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
US11484581B2 (en) 2017-06-02 2022-11-01 Arizona Board Of Regents On Behalf Of Arizona State University Method to create personalized canine cancer vaccines
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
JP7334124B2 (ja) * 2017-06-21 2023-08-28 トランジェーヌ 個別化ワクチン
WO2019014581A1 (en) 2017-07-14 2019-01-17 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
WO2019018801A1 (en) 2017-07-21 2019-01-24 Berkeley Lights Inc. SYNTHETIC SURFACES FOR PRESENTING ANTIGENS, COVALENTLY FUNCTIONALIZED SURFACES, ACTIVATED T CELLS AND USES THEREOF
EP3658683A4 (en) 2017-07-25 2021-04-21 California Institute of Technology DISCOVERY OF TROGOCYTOSIS-MEDIATED EPITOPIA
WO2019036043A2 (en) * 2017-08-16 2019-02-21 Medgenome Inc. METHOD FOR GENERATING A COCKTAIL OF PERSONALIZED ANTICANCER VACCINES FROM TUMOR DERIVED GENETIC MODIFICATIONS FOR THE TREATMENT OF CANCER
WO2019055618A1 (en) 2017-09-15 2019-03-21 Arizona Board Of Regents On Behalf Of Arizona State University METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY
CA3076918A1 (en) * 2017-10-02 2019-04-11 Curematch, Inc. Method of prediction of tumor-derived neo-peptide antigenicity and/or immunogenicity using mutational signature patterns
WO2019070834A1 (en) * 2017-10-06 2019-04-11 David Weiner MONOCLONAL DNA ANTIBODIES TARGETING CTLA-4 FOR THE TREATMENT AND PREVENTION OF CANCER
WO2019075112A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
CN111801415A (zh) * 2017-11-06 2020-10-20 路德维格癌症研究院 扩增淋巴细胞的方法
WO2019094396A1 (en) * 2017-11-07 2019-05-16 Nektar Therapeutics Immunotherapeutic combination for treating cancer
CN120519386A (zh) 2017-11-08 2025-08-22 百欧恩泰美国公司 T细胞制备组合物和方法
AU2018373154B2 (en) 2017-11-22 2025-08-07 Seattle Project Corp. Reducing junction epitope presentation for neoantigens
CN109682978B (zh) * 2017-11-30 2020-07-03 四川康德赛医疗科技有限公司 一种肿瘤突变肽mhc亲和力预测方法及其应用
WO2019126186A1 (en) 2017-12-18 2019-06-27 Neon Therapeutics, Inc. Neoantigens and uses thereof
CA3087537A1 (en) 2018-01-04 2019-07-11 Jan-willem THEUNISSEN Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
US11573230B2 (en) 2018-01-26 2023-02-07 Nantcell, Inc. Rapid verification of virus particle production for a personalized vaccine
US20210046177A1 (en) 2018-01-26 2021-02-18 Nantcell, Inc. Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy
CN108491689B (zh) * 2018-02-01 2019-07-09 杭州纽安津生物科技有限公司 基于转录组的肿瘤新抗原鉴定方法
EP3759131A4 (en) * 2018-02-27 2021-12-01 Gritstone bio, Inc. NEO-ANTIGEN IDENTIFICATION USING PAN-ALLEL MODELS
WO2019210055A2 (en) 2018-04-26 2019-10-31 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
JP2021525549A (ja) * 2018-05-25 2021-09-27 ザ ウィスター インスティテュート 腫瘍特異的ネオ抗原およびその使用方法
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
TW202015719A (zh) 2018-06-19 2020-05-01 美商尼恩醫療公司 新抗原及其用途
WO2020022900A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for kidney cancer
US20210252123A1 (en) 2018-07-26 2021-08-19 Frame Pharmaceuticals B.V. ARID1A, CDKN2A, KMT2B, KMT2D, TP53 and PTEN VACCINES FOR CANCER
CA3106570A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for uterine cancer
CA3106562A1 (en) * 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Off-the-shelf cancer vaccines
IL321692A (en) 2018-07-26 2025-08-01 Curevac Netherlands B V Cancer vaccines for colorectal cancer
CA3106564A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
CN109021062B (zh) * 2018-08-06 2021-08-20 倍而达药业（苏州）有限公司 一种肿瘤新抗原的筛选方法
EP3844761A1 (en) 2018-08-31 2021-07-07 Guardant Health, Inc. Microsatellite instability detection in cell-free dna
GB201815041D0 (en) 2018-09-14 2018-10-31 Scancell Ltd Epitopes
TW202028224A (zh) * 2018-09-17 2020-08-01 德商英麥提克生物技術股份有限公司 B*44限制肽在抗癌免疫治療的用途和相關方法
AU2019343994A1 (en) 2018-09-21 2021-05-13 Berkeley Lights, Inc. Functionalized well plate, methods of preparation and use thereof
SG11202101965QA (en) 2018-09-27 2021-04-29 Vaccibody As Method for selecting neoepitopes
CN113272417A (zh) 2018-10-18 2021-08-17 伯克利之光生命科技公司 原抗原呈递合成表面、活化的t细胞及其用途
US20200188435A1 (en) 2018-11-08 2020-06-18 Nexlmmune, Inc. T cell compositions with improved phenotypic properties
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
CN109706065A (zh) * 2018-12-29 2019-05-03 深圳裕策生物科技有限公司 肿瘤新生抗原负荷检测装置及存储介质
US20200291355A1 (en) 2019-02-20 2020-09-17 Rubius Therapeutics, Inc. Engineered erythroid cells including loadable antigen-presenting polypeptides and methods of use
CN111621564B (zh) * 2019-02-28 2022-03-25 武汉大学 一种鉴定有效肿瘤新抗原的方法
US12427195B1 (en) * 2019-03-11 2025-09-30 La Jolla Institute For Immunology Methods of neoantigen identification
US20220130489A1 (en) * 2019-03-12 2022-04-28 Syntekabio,Inc. System and method for providing neoantigen immunotherapy information by using artificial-intelligence-model-based molecular dynamics big data
WO2020227233A2 (en) * 2019-05-03 2020-11-12 Richard Guilhem Neoantigens in cancer
WO2020227255A1 (en) * 2019-05-06 2020-11-12 The Regents Of The University Of Michigan Targeted therapy
KR20220016137A (ko) 2019-05-30 2022-02-08 그릿스톤 바이오, 인코포레이티드 변형된 아데노바이러스
CN112011833B (zh) * 2019-05-30 2024-04-26 上海桀蒙生物技术有限公司 筛选和分离肿瘤新生抗原的方法
CN110322925B (zh) * 2019-07-18 2021-09-03 杭州纽安津生物科技有限公司 一种预测融合基因产生新生抗原的方法
CN110706747B (zh) * 2019-09-17 2021-09-07 北京橡鑫生物科技有限公司 检测肿瘤新生抗原多肽的方法和装置
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
US11920202B2 (en) 2020-04-09 2024-03-05 University Of Connecticut Unbiased identification of tumor rejection mediating neoepitopes
WO2021228999A1 (en) * 2020-05-12 2021-11-18 Institut Curie Neoantigenic epitopes associated with sf3b1 mutations
WO2021230247A1 (ja) * 2020-05-12 2021-11-18 大日本住友製薬株式会社 癌を処置するための医薬組成物
US20230210968A1 (en) 2020-06-11 2023-07-06 Massachusetts Institute Of Technology Ribonucleoprotein approach to boost the sting signaling for cancer immunotherapy
WO2022032196A2 (en) 2020-08-06 2022-02-10 Gritstone Bio, Inc. Multiepitope vaccine cassettes
WO2022036137A1 (en) 2020-08-13 2022-02-17 Biontech Us Inc. T cell manufacturing compositions and methods
US20230323431A1 (en) * 2020-08-31 2023-10-12 World Biotech Regenerative Medical Group Limited Personalized Immunogenic Compositions and Methods for Producing and Using Same
KR102552632B1 (ko) * 2020-11-06 2023-07-06 사회복지법인 삼성생명공익재단 중추신경계 림프종을 진단하기 위한 마커, 이를 포함하는 중추신경계 림프종 진단 키트 및 중추신경계 림프종을 진단하는 방법
AU2022245391A1 (en) * 2021-03-26 2023-10-12 The Translational Genomics Research Institute Methods and compounds for neoantigen vaccines
JP2024517793A (ja) 2021-04-30 2024-04-23 ティゲン・ファーマ・ソシエテ・アノニム 単一容器リンパ球拡大
US20230173046A1 (en) * 2021-05-27 2023-06-08 Amazon Technologies, Inc. Multicomponent chemical composition of a peptide-based neoantigen vaccine
CA3227081A1 (en) 2021-08-24 2023-03-02 Irena RABE In vitro transcription technologies
CN115772564B (zh) * 2021-09-08 2023-08-18 广州市基准医疗有限责任公司 用于辅助检测肺癌体细胞atm基因融合突变的甲基化生物标记物及其应用
WO2023068931A1 (en) 2021-10-21 2023-04-27 Curevac Netherlands B.V. Cancer neoantigens
CN116287158A (zh) * 2021-12-08 2023-06-23 初源海生物科技(深圳)有限公司 一种新抗原鉴定和疗效预测方法
JP2025509607A (ja) 2022-03-14 2025-04-11 ジェネレーション バイオ カンパニー 異種プライムブーストワクチン組成物及び使用の方法
WO2024077256A1 (en) 2022-10-07 2024-04-11 The General Hospital Corporation Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
EP4612276A1 (en) 2022-11-02 2025-09-10 Tigen Pharma SA Expansion of lymphocytes
EP4474016A1 (en) 2023-06-07 2024-12-11 Julius-Maximilians-Universität Würzburg Strategies to target extracellularly accessible ras protein
WO2024261339A1 (en) 2023-06-23 2024-12-26 Tigen Pharma Sa Lymphocyte-stimulatory matrix (lsm) and uses thereof for expansion of lymphocyte populations
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US221332A (en) 1879-11-04 Improvement in fire-escapes
US911A (en) 1838-09-12 Mode of fastening bedsteabs
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4844893A (en) 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
EP0800830A3 (en) 1989-11-03 1999-03-17 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
WO1993025673A1 (en) 1992-06-04 1993-12-23 The Regents Of The University Of California In vivo gene therapy with intron-free sequence of interest
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US5589406A (en) 1993-07-30 1996-12-31 Ag Technology Co., Ltd. Method of making TFT display
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
CN1367830A (zh) * 1998-10-05 2002-09-04 路德维哥癌症研究院 癌症相关抗原及其应用
NO309798B1 (no) 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
KR100773109B1 (ko) * 1999-05-06 2007-11-02 웨이크 포리스트 유니버시티 면역 반응을 유발하는 항원을 동정하기 위한 조성물과 방법
ATE512666T1 (de) * 1999-06-29 2011-07-15 Epimmune Inc Hla-bindende peptide und ihre verwendungen
WO2001055177A2 (en) * 2000-01-28 2001-08-02 Statens Serum Institut Methods to identify ctl epitopes of hiv
US20040071671A1 (en) * 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
AU2002336446B2 (en) * 2001-09-06 2008-03-06 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
PT1512014E (pt) 2002-06-13 2009-11-10 Merck Patent Gmbh Método de identificação de alo-antigénios e sua utilização para terapia de cancro e transplante
PL1620456T3 (pl) * 2003-04-18 2014-06-30 Ose Pharma Int Sa Peptydy antygenu związanego z nowotworem HLA-A2 i kompozycje
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US7220549B2 (en) 2004-12-30 2007-05-22 Helicos Biosciences Corporation Stabilizing a nucleic acid for nucleic acid sequencing
US7283337B2 (en) 2005-03-04 2007-10-16 Headway Technologies, Inc. Abutted exchange bias design for sensor stabilization
KR101498834B1 (ko) 2005-05-09 2015-03-05 오노 야꾸힝 고교 가부시키가이샤 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
US20070112754A1 (en) 2005-11-15 2007-05-17 Honeywell International Inc. Method and apparatus for identifying data of interest in a database
WO2007101227A2 (en) * 2006-02-27 2007-09-07 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
CA2647282A1 (en) * 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US9045556B2 (en) 2007-02-07 2015-06-02 Nec Corporation Therapeutic agent for cancer
CN101801413A (zh) 2007-07-12 2010-08-11 托勒克斯股份有限公司 采用gitr结合分子的联合疗法
MX2010002001A (es) * 2007-08-20 2010-03-11 Oncotherapy Science Inc Peptido cdca1 y agente farmaceutico que comprende elmismo.
WO2009086472A2 (en) 2007-12-28 2009-07-09 John Wayne Cancer Institute Use of methylation status of mint loci and tumor-related genes as a marker for melanoma and breast cancer
WO2009102909A2 (en) * 2008-02-15 2009-08-20 Board Of Regents, The University Of Texas System Anti-cancer vaccines
ES2840750T3 (es) 2008-09-22 2021-07-07 Baylor College Medicine Métodos y composiciones para generar una respuesta inmune induciendo CD40 y adaptadores del receptor de reconocimiento de patrones
US8369279B2 (en) 2010-03-10 2013-02-05 Broadcom Corporation Method and system for iterative multiple frequency hypothesis testing with cell-ID detection in an E-UTRA/LTE UE receiver
CN102652015B (zh) 2009-12-10 2016-08-03 默克专利有限公司 包含寡肽、优选西仑吉肽的药物组合物
US9023802B2 (en) 2009-12-14 2015-05-05 Immatics Biotechnologies Gmbh HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
DK3023788T3 (da) * 2010-05-14 2020-04-27 Massachusetts Gen Hospital Sammensætninger af tumorspecifikke neoantigener til anvendelse ved behandling af tumorer
MX343671B (es) 2010-06-02 2016-11-16 Abraxis Bioscience Llc * Metodos de tratamiento de cancer de vejiga.
GB2506760B (en) 2011-01-14 2015-07-22 Genefirst Ltd Allele specific primers for EGFR exon 21 specific mutations
JP2014526892A (ja) 2011-08-18 2014-10-09 ネステク ソシエテ アノニム 対立遺伝子多型を検出するための組成物及び方法
AU2013221642A1 (en) 2012-02-15 2014-09-25 Janssen Diagnostics, Llc Highly sensitive method for detecting low frequency mutations
WO2013173223A1 (en) 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
WO2014150924A2 (en) 2013-03-15 2014-09-25 The Broad Institute, Inc. Accurate typing of hla through exome sequencing
CA2953277A1 (en) 2014-06-05 2015-12-10 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Means and methods for determining t cell recognition
CN106715723B (zh) 2014-08-07 2021-03-30 法马西斯特有限责任公司 测定样品中pik3ca突变状态的方法
US20190099475A1 (en) 2015-04-08 2019-04-04 Nantomics, Llc Cancer neoepitopes
CN108138221B (zh) 2015-05-10 2021-11-05 康代思锐公司 用于检测核酸的超高灵敏度探针
TW202241500A (zh) 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法

Also Published As

Publication number Publication date
US20160331822A1 (en) 2016-11-17
KR20210129254A (ko) 2021-10-27
JP5948319B2 (ja) 2016-07-06
CA3197245A1 (en) 2011-11-17
JP6943545B2 (ja) 2021-10-06
KR20180105743A (ko) 2018-09-28
KR102017898B1 (ko) 2019-09-04
KR102095670B1 (ko) 2020-03-31
ES2788863T3 (es) 2020-10-23
KR20130119845A (ko) 2013-11-01
JP2022044632A (ja) 2022-03-17
EP3023788A1 (en) 2016-05-25
EP4623996A3 (en) 2025-12-31
KR20190133281A (ko) 2019-12-02
US20160008447A1 (en) 2016-01-14
JP2024045573A (ja) 2024-04-02
ES2564841T3 (es) 2016-03-29
JP2016156828A (ja) 2016-09-01
JP2013530943A (ja) 2013-08-01
EP3699266B1 (en) 2025-07-02
BR112012029066A2 (pt) 2020-09-01
CA2797868A1 (en) 2011-11-17
JP7801134B2 (ja) 2026-01-16
WO2011143656A3 (en) 2012-08-23
PL3023788T3 (pl) 2020-07-27
AU2011252795B2 (en) 2015-09-03
HUE049886T2 (hu) 2020-10-28
EP4623996A2 (en) 2025-10-01
PT3023788T (pt) 2020-05-18
AU2011252795A1 (en) 2012-11-08
EP2569633A4 (en) 2014-05-14
US20200069783A1 (en) 2020-03-05
US20190060432A1 (en) 2019-02-28
CN103180730A (zh) 2013-06-26
DK3023788T3 (da) 2020-04-27
US20180055922A1 (en) 2018-03-01
JP2019135494A (ja) 2019-08-15
US20110293637A1 (en) 2011-12-01
CA2797868C (en) 2023-06-20
BR122021014039B1 (pt) 2021-12-14
US10426824B1 (en) 2019-10-01
EP3023788B1 (en) 2020-02-12
WO2011143656A2 (en) 2011-11-17
CN105648056A (zh) 2016-06-08
EP2569633A2 (en) 2013-03-20
EP2569633B1 (en) 2016-02-10
US20200016251A1 (en) 2020-01-16
CN103180730B (zh) 2016-03-02
US9115402B2 (en) 2015-08-25
EP3699266A1 (en) 2020-08-26
KR102447139B1 (ko) 2022-09-23
JP7008049B2 (ja) 2022-02-10
KR102315754B1 (ko) 2021-10-22

Similar Documents

Publication Publication Date Title
ES3038392T3 (en) Neoantigen specific cytotoxic t cells for use in treating cancer
AU2024219404A1 (en) Compositions and methods of identifying tumor specific neoantigens
HK40036803A (en) Neoantigen specific cytotoxic t cells for use in treating cancer